BiotechTube

PTC299

Phase 2Terminated
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neurofibromatosis 2

Conditions

Neurofibromatosis 2

Trial Timeline

Jul 31, 2009 → Mar 31, 2012

NCT ID
NCT00911248

About PTC299

PTC299 is a phase 2 stage product being developed by United Therapeutics for Neurofibromatosis 2. The current trial status is terminated. This product is registered under clinical trial identifier NCT00911248. Target conditions include Neurofibromatosis 2.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT00911248Phase 2Terminated
NCT00508586Phase 1Completed

Competing Products

20 competing products in Neurofibromatosis 2

See all competitors
ProductCompanyStageHype Score
SelumetinibAstraZenecaPhase 2
52
SelumetinibAstraZenecaPhase 1
33
SelumetinibAstraZenecaPhase 1
33
AZD2014AstraZenecaPhase 2
52
Selumetinib + PlaceboAstraZenecaPhase 2
52
Treatment A + Treatment B + Treatment C + Treatment D + AcetaminophenAstraZenecaPhase 1
33
SelumetinibAstraZenecaPhase 1/2
41
SelumetinibAstraZenecaPhase 1
33
Selumetinib granule formulation + Selumetinib capsule formulationAstraZenecaPhase 1/2
41
SelumetinibAstraZenecaPhase 3
77
Everolimus (RAD001) , Afinitor®NovartisPhase 2
52
RAD001: EverolimusNovartisPhase 2
52
RAD001, everolimusNovartisPhase 2
52
TasignaNovartisPhase 1
33
TrametinibNovartisPhase 2
52
Everolimus (RAD001)NovartisPhase 2
52
Sutent®/SunitinibPfizerPhase 2
51
Sorafenib (Nexavar)BayerPhase 2
49
REC-2282 + PlaceboRecursion PharmaceuticalsPhase 2/3
60
BinimetinibPacific BiosciencesPhase 2
44

Other Products from United Therapeutics

TreprostinilApproved
82
RemodulinApproved
82
Remodulin (treprostinil sodium)Approved
82
Intravenous TreprostinilApproved
82
Intravenous/Subcutaneous Treprostinil; Oral TreprostinilApproved
82